CEO and President Joe Payne outlined the company’s current focus on messenger RNA (mRNA) therapeutics, emphasizing a leaner ...
Arcturus Therapeutics Holdings (ARCT) is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, ...
About 1 in 10 cases of COVID-19 nationwide is caused by an emerging coronavirus strain, XBB.1.16. The World Health Organization has elevated this strain of omicron to one of two "circulating variants ...
State of Electronics] have released their latest video about ARCTURUS, the 14th video in their series The Computer History of ...
In late 2025, Arcturus Therapeutics Holdings Inc. filed an omnibus shelf registration of up to US$500 million, covering ...
The Arcturus COVID-19 variant has arrived in the United States and is here to stay, according to experts. While it's unclear whether it will drive a summer surge, some doctors are warning that the ...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease ...
Hosted on MSN
Arcturus outlines pivotal trial plans and advances CF and OTC programs with regulatory meetings expected in 2026
Earnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 CEO Joseph E. Payne reported that the ARCT-032 program for Cystic Fibrosis (CF) has completed enrollment and dosing for the 5 ...
Face east around 9-9:30 p.m. in mid-April and you can't miss shimmering orange Arcturus, the brightest star in the constellation Bootes the Bear Guardian. Two fists to the lower left of Arcturus, look ...
Over the next week skywatchers can expect to see a brilliant star that sparkles with a golden yellow or topaz hue that is situated about one-third of the way up from the eastern horizon as darkness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback